EASL Clinical Practice Guidelines: Management of chronic hepatitis B European Association for the Study of the Liver  Journal of Hepatology  Volume 50, Issue 2, Pages 227-242 (February 2009) DOI: 10.1016/j.jhep.2008.10.001 Copyright © 2009 Terms and Conditions

Fig. 1 Rates of HBe seroconversion, undetectable HBV DNA and normal ALT at one year of therapy with pegylated interferon alpha-2a (PEG-IFN), lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (LdT) and tenofovir (TDF) in HBeAg-positive patients with CHB in randomized clinical trials. These trials used different HBV DNA assays and they were not head-to-head comparisons for all the drugs; thus, these numbers are only indicative and should be considered with caution. Journal of Hepatology 2009 50, 227-242DOI: (10.1016/j.jhep.2008.10.001) Copyright © 2009 Terms and Conditions

Fig. 2 Rates of undetectable HBV DNA and normal ALT at one year of therapy with pegylated interferon alpha-2a (PEG-IFN), lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (LdT) and tenofovir (TDF) in HBeAg-negative patients with CHB in randomized clinical trials. These trials used different HBV DNA assays and they were not head-to-head comparisons for all the drugs; thus, these numbers are only indicative and should be considered with caution. Journal of Hepatology 2009 50, 227-242DOI: (10.1016/j.jhep.2008.10.001) Copyright © 2009 Terms and Conditions

Fig. 3 Cumulative incidence of HBV resistance to lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (LdT) and tenofovir (TDF) in published pivotal trials in NUC-naive patients. For method of calculation, see ref. [29]. These trials included different populations, used different exclusion criteria and different follow-up endpoints. Journal of Hepatology 2009 50, 227-242DOI: (10.1016/j.jhep.2008.10.001) Copyright © 2009 Terms and Conditions